摘要
目的研究莪术醇对子宫内膜异位症(EMS)模型大鼠腹腔液中炎症因子的影响,探讨本药对EMS的治疗机制。方法取成年雌性SD大鼠,以自体移植法制备EMS模型。将造模成功的大鼠随机分为模型组、莪术醇组(20mg/kg),另设假手术组,每组10只。各组大鼠每日灌胃给药1次,连续4周。末次给药后,大鼠麻醉,收集腹腔液,检测其中巨噬细胞趋化蛋白-1(MCP-1)、巨噬细胞游走抑制因子(MIF)、肿瘤坏死因子(TNF)-α、白细胞介素(IL)-1β和IL-6含量,假手术组大鼠取在位子宫,EMS大鼠取异位子宫内膜组织,HE染色观察病理变化,并以免疫组化染色检测内膜组织中TNF-α表达,Real-time PCR检测内膜组织中成纤维细胞生长因子2(FGF-2)mRNA表达。结果与模型组相比,莪术醇组大鼠异位内膜萎缩,腹腔液中MCP-1、MIF、TNF-α、IL-1β、IL-6含量和内膜组织中TNF-α表达、FGF-2 mRNA表达水平均明显降低(P<0.05)。结论莪术醇能够改善实验性大鼠EMS,其作用机制可能与抑制腹腔微环境中炎症反应有关。
Objective To study the effect of curcumenol on the inflammatory factors in peritoneal fluid of rats with endometriosis (EMS), and to explore its therapeutic mechanism. Methods Adult female SD rats were used to prepare EMS model by autotransplantation. The EMS model rats were randomly divided into model group and curcumenol group (20 mg/ kg), and another sham operation group was set up, 10 rats in each group. Rats in each group were given the drug by intragastric administration once a day for four weeks. After the last administration, the rats were anesthetized, and samples of the abdominal fluid were collected. Pathological morphology of ectopic endometrium in rats was observed. The contents of monocyte chemotactic protein-1 (MCP-1), macrophage migration-inhibitory factors (MIF), tumor necrosis factor-alpha (TNF)-α, interleukin (IL)-1β and IL-6 in peritoneal fluid were detected. The TNF-α expression in endometrial tissue was detected by immunohistochemistry, and the fibroblast growth factor 2 (FGF-2) mRNA expression was detected by real-time PCR. Results Compared to the model group, the ectopic endometrium atrophy was found in curcumenol group, the contents of MCP-1, MIF, TNF -α, IL-1β, IL-6 in the peritoneal fluid of rats and the TNF -α expression, the FGF-2 mRNA expression in endometrial tissues were significantly decreased in curcumenol group (P<0.05). Conclusion The curcumenol can inhibit the inflammatory reaction in the peritoneal microenvironment, which may be related to its treatment effect on EMS.
作者
聂晓博
马怡坤
赵娜
胡彬
刘姣
刘晓兰
NIE Xiao-bo;MA Yi-kun;ZHAO Na;HU Bin;LIU Jiao;LIU Xiao-lan(Department of Traditional Chinese Medicine, Shijiazhuang Medical College, Shijiazhuang 050599, China;Infirmary, Shijiazhuang Information Engineering Vocational College;Department of TCM Pharmacology, Hebei University of Chinese Medicine)
出处
《天津医药》
CAS
北大核心
2019年第9期913-917,共5页
Tianjin Medical Journal
基金
国家自然科学基金资助项目（81803822）
河北省高等学校科学技术研究项目（QN2017112）
河北省中医药管理局计划项目（2018209）
